Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Alpha-synuclein-induced stress sensitivity renders the Parkinson’s disease brain susceptible to neurodegeneration
Modestos Nakos Bimpos, Katerina Karali, Christine Antoniou, Dionysios Palermos, Maria Fouka, Anastasios Delis, Iason Tzieras, George Chrousos, Yassemi Koutmani, Leonidas Stefanis, Alexia Polissidis (2024). Alpha-synuclein-induced stress sensitivity renders the Parkinson’s disease brain susceptible to neurodegeneration. , 12(1), DOI: https://doi.org/10.1186/s40478-024-01797-w.
Article203 days agoStress system and related biomarkers in Parkinson's disease
Anastasia Bougea, Leonidas Stefanis, George Chrousos (2022). Stress system and related biomarkers in Parkinson's disease. , DOI: https://doi.org/10.1016/bs.acc.2022.07.004.
Article203 days agoFingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data
Maria Gontika, Charalampos Skarlis, Nikolaos Markoglou, Maria‐Eleftheria Evangelopoulos, Georgios Velonakis, George Chrousos, Marinos C. Dalakas, Leonidas Stefanis, Maria Anagnostouli (2021). Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. , 43(4), DOI: https://doi.org/10.1007/s10072-021-05623-2.
Article203 days agoFirst-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center
Charalampos Skarlis, Nikolaos Markoglou, Maria Gontika, Anastasia Bougea, Serafeim Katsavos, Artemios Artemiadis, George Chrousos, Marinos C. Dalakas, Leonidas Stefanis, Maria Anagnostouli (2022). First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center. , 44(2), DOI: https://doi.org/10.1007/s10072-022-06431-y.
Article203 days agoNatalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study
Maria Gontika, Charalampos Skarlis, Nikolaos Markoglou, Dimitrios Tzanetakos, Aglaia G Vakrakou, Panagiotis Toulas, Georgios Koutsis, Maria‐Eleftheria Evangelopoulos, Roser Pons, Efthimios Dardiotis, George Chrousos, Marinos C. Dalakas, Leonidas Stefanis, Maria Anagnostouli (2022). Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study. , 395(8), DOI: https://doi.org/10.1007/s00210-022-02238-y.
Article203 days ago